Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD).

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial.

An intensive BP reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and older with untreated hypertension.

The FDA has extended the review period for the NDA for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

Implantable cardioverter-defibrillator therapy in patients with Brugada syndrome is effective for prevention of fatal arrhythmias.

A scientific statement regarding risk-based primary prevention of heart failure has been published by the American Heart Association.

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.